<p>Gyre Therapeutics, Inc.（納斯達克代碼：GYRE - 獲取免費報告）週五股價下跌 4.7%。該股最低交易價為$9.63，最後交易價為$9.74。在午盤交易中，共成交 48,133 股，較平均交易量 80,171 股下降了 40%。該股此前收盤價為$10.22。</p>
<p>獲取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>另外，Noble Financial 在 3 月 11 日（星期二）的一份研究報告中開始覆蓋 Gyre Therapeutics 的股票。他們對該股給予了 “跑贏大盤” 的評級。</p>
<p><strong>查看我們最新的 GYRE 股票分析</strong></p>
<h2>Gyre Therapeutics 股價下跌 4.4%</h2>
<p>該公司的 50 日移動平均價格為$11.31，200 日移動平均價格為$12.23。</p>
<p>Gyre Therapeutics（納斯達克代碼：GYRE - 獲取免費報告）最近在 3 月 17 日（星期一）發佈了季度財報。公司報告每股收益（EPS）為$0.01，低於分析師一致預期的$0.04，差距為$0.03。該季度的收入為 2787 萬美元，而一致預期為 2350 萬美元。Gyre Therapeutics 的淨利潤率為-84.57%，股本回報率為-118.43%。</p>
<h2>Gyre Therapeutics 內部活動</h2>
<p>在相關消息中，總裁馬松江於 12 月 26 日（星期四）出售了 2000 股公司的股票，交易平均價格為$12.70，總價值為$25,400.00。交易完成後，總裁現在持有 2928467 股公司股票，價值$37,191,530.90。此次交易代表其持股比例下降了 0.07%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。內部人士在上個季度共出售了 36,054 股公司股票，價值$411,597。19.52% 的股票由內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>大型投資者最近增加或減少了對該公司的持股。SBI 證券有限公司在第四季度購買了 Gyre Therapeutics 的新頭寸，金額約為$1,225,000。FMR LLC 在第三季度購買了 Gyre Therapeutics 的新頭寸，金額約為$47,000。Charles Schwab 投資管理公司在第三季度將其在 Gyre Therapeutics 的持股增加了 392.2%。Charles Schwab 投資管理公司現在持有 113,648 股公司股票，價值$1,425,000，此前在上個季度又購買了 90,557 股。State Street Corp 在第三季度將其在 Gyre Therapeutics 的持股增加了 8.8%。State Street Corp 現在持有 104,490 股公司股票，價值$1,310,000，此前在上個季度又購買了 8,412 股。最後，巴克萊 PLC 在第三季度將其在 Gyre Therapeutics 的持股增加了 281.8%。巴克萊 PLC 現在持有 9,288 股公司股票，價值$116,000，此前在上個季度又購買了 6,855 股。機構投資者持有公司 23.99% 的股票。</p>
<h2>Gyre Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Gyre Therapeutics, Inc.是一家生物製藥公司，主要專注於 Hydronidone 的開發和商業化，以治療美國的代謝功能障礙相關性脂肪肝炎。其 Hydronidone 也正在評估用於治療一系列慢性肝病引起的肝纖維化。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票超過 Gyre Therapeutics</li>
<li>現在購買的 3 只沃倫·巴菲特股票</li>
<li>聯邦快遞再次對其股價造成重創</li>
<li>什麼是股息冠軍？如何投資於冠軍</li>
<li>分析師對火箭實驗室保持樂觀，底部跡象顯現</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>美光股票將在今年重新測試歷史高點</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Gyre Therapeutics 嗎？</h2>
<p>在考慮 Gyre Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Gyre Therapeutics 並不在名單上。</p>
<p>雖然 Gyre Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

GYRE

<p>Gyre Therapeutics (NASDAQ:GYRE) 的股價下跌了 4.7%，至 9.74 美元，交易量較平均水平下降了 40%。該公司報告的季度每股收益為 0.01 美元，未達到預期，但收入為 2787 萬美元，超出預期。內部人士最近出售了股票，機構投資者持有 23.99% 的股份。分析師維持 “買入” 評級，但有些人建議有更好的投資選擇。該公司專注於開發用於肝病治療的 Hydronidone</p>

<p>Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares traded down 4.7% on Friday . The stock traded as low as $9.63 and last traded at $9.74. 48,133 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 80,171 shares. The stock had previously closed at $10.22.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc.（納斯達克代碼：GYRE - 獲取免費報告）週五股價下跌 4.7%。該股最低交易價為$9.63，最後交易價為$9.74。在午盤交易中，共成交 48,133 股，較平均交易量 80,171 股下降了 40%。該股此前收盤價為$10.22。</p>
</div><p>Get <strong>Gyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Gyre Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an &#34;outperform&#34; rating on the stock.</p>
<div class="lb-trans"><p>另外，Noble Financial 在 3 月 11 日（星期二）的一份研究報告中開始覆蓋 Gyre Therapeutics 的股票。他們對該股給予了 “跑贏大盤” 的評級。</p>
</div><p><strong>View Our Latest Stock Analysis on GYRE</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 GYRE 股票分析</strong></p>
</div><h2>Gyre Therapeutics Stock Down 4.4 %</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 股價下跌 4.4%</h2>
</div><p>The business's 50 day moving average price is $11.31 and its two-hundred day moving average price is $12.23.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為$11.31，200 日移動平均價格為$12.23。</p>
</div><p>Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). The business had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.</p>
<div class="lb-trans"><p>Gyre Therapeutics（納斯達克代碼：GYRE - 獲取免費報告）最近在 3 月 17 日（星期一）發佈了季度財報。公司報告每股收益（EPS）為$0.01，低於分析師一致預期的$0.04，差距為$0.03。該季度的收入為 2787 萬美元，而一致預期為 2350 萬美元。Gyre Therapeutics 的淨利潤率為-84.57%，股本回報率為-118.43%。</p>
</div><h2>Insider Activity at Gyre Therapeutics</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 內部活動</h2>
</div><p>In related news, President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders sold a total of 36,054 shares of company stock worth $411,597 in the last quarter. 19.52% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，總裁馬松江於 12 月 26 日（星期四）出售了 2000 股公司的股票，交易平均價格為$12.70，總價值為$25,400.00。交易完成後，總裁現在持有 2928467 股公司股票，價值$37,191,530.90。此次交易代表其持股比例下降了 0.07%。該出售在向證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。內部人士在上個季度共出售了 36,054 股公司股票，價值$411,597。19.52% 的股票由內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new position in Gyre Therapeutics during the 4th quarter worth approximately $1,225,000. FMR LLC bought a new position in Gyre Therapeutics during the 3rd quarter worth approximately $47,000. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp raised its holdings in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Finally, Barclays PLC raised its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares during the last quarter. Institutional investors own 23.99% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該公司的持股。SBI 證券有限公司在第四季度購買了 Gyre Therapeutics 的新頭寸，金額約為$1,225,000。FMR LLC 在第三季度購買了 Gyre Therapeutics 的新頭寸，金額約為$47,000。Charles Schwab 投資管理公司在第三季度將其在 Gyre Therapeutics 的持股增加了 392.2%。Charles Schwab 投資管理公司現在持有 113,648 股公司股票，價值$1,425,000，此前在上個季度又購買了 90,557 股。State Street Corp 在第三季度將其在 Gyre Therapeutics 的持股增加了 8.8%。State Street Corp 現在持有 104,490 股公司股票，價值$1,310,000，此前在上個季度又購買了 8,412 股。最後，巴克萊 PLC 在第三季度將其在 Gyre Therapeutics 的持股增加了 281.8%。巴克萊 PLC 現在持有 9,288 股公司股票，價值$116,000，此前在上個季度又購買了 6,855 股。機構投資者持有公司 23.99% 的股票。</p>
</div><h2>Gyre Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Gyre Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.</p>
<div class="lb-trans"><p>Gyre Therapeutics, Inc.是一家生物製藥公司，主要專注於 Hydronidone 的開發和商業化，以治療美國的代謝功能障礙相關性脂肪肝炎。其 Hydronidone 也正在評估用於治療一系列慢性肝病引起的肝纖維化。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Gyre Therapeutics</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>FedEx Delivers Another Crushing Blow to Its Stock Price</li>
<li>What Are Dividend Champions? How to Invest in the Champions</li>
<li>Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Micron Stock Will Retest All-Time Highs This Year</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Gyre Therapeutics</li>
<li>現在購買的 3 只沃倫·巴菲特股票</li>
<li>聯邦快遞再次對其股價造成重創</li>
<li>什麼是股息冠軍？如何投資於冠軍</li>
<li>分析師對火箭實驗室保持樂觀，底部跡象顯現</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>美光股票將在今年重新測試歷史高點</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Gyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Gyre Therapeutics 嗎？</h2>
</div><p>Before you consider Gyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Gyre Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Gyre Therapeutics 並不在名單上。</p>
</div><p>While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Gyre Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Gyre Therapeutics (NASDAQ:GYRE) 股價下跌 4.7% - 現在是賣出的時候嗎？